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poorly understood. Here, we identiﬁed a novel role of ribavirin in the communication between
p53 and the mammalian target of rapamycin (mTOR) signaling. Ribavirin activates p53 by stimulat-
ing mTOR and promoting the interaction between mTOR and p53. Activated p53 stimulates the tran-
scription of IFN regulatory factor 9 and subsequently enhances IFN signaling. Furthermore,
ribavirin-induced activation of mTOR and p53 enhances IFN-dependent signaling for the IFN-a/riba-
virin combined treatment. We conclude that ribavirin enhances activities of mTOR and p53, which
may account for its antiviral and antitumor effects.
Structured summary:
MINT-7222801:mTOR (uniprotkb:P42345) physically interacts (MI:0914) with raptor (uniprotkb:Q8N122)
by anti bait coimmunoprecipitation (MI:0006)
MINT-7222793: mTOR (uniprotkb:P42345) physically interacts (MI:0914) with RICTOR (uni-
protkb:Q8N6M7) by anti bait coimmunoprecipitation (MI:0006)
MINT-7222784:mTOR (uniprotkb:P42345) physically interacts (MI:0914) with P53 (uniprotkb:P04637) by
anti bait coimmunoprecipitation (MI:0006)
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumor suppressor p53 plays a major role in protecting the
integrity of the genome. P53 exhibits the antiproliferative effects
by regulating guanine nucleotide biosynthesis and the balance of
cellular GTP pool probably through the suppression of inosine
monophosphate dehydrogenase (IMPDH) transcription [1]. In addi-
tion, several studies have shown that p53 communicates directly
with the mammalian target of rapamycin (mTOR) signaling path-
ways in sensing and integrating signals from nutrient and apopto-
sis [2]. Therefore, mTOR activity seems to be critical for regulating
p53 functions in metabolism and responses to environmental stim-
uli. The induction of p53 by interferon (IFN) relies on the IFN-stim-
ulated response elements (ISREs) in p53 promoter [3]. A recent
study has shown that a central component of IFN signaling path-chemical Societies. Published by E
itute of Clinical Medicine,
han South Rd., Taipei 10002,way-IFN regulatory factor 9 (IRF9), is a direct target of p53. It
was also demonstrated that functional p53 is required to enhance
the expression of IFN-stimulated genes (ISGs) and has an impact on
the IFN-dependent antiviral response [4].
Ribavirin plus pegylated IFN-a has become the current standard
treatment for patients with chronic hepatitis C [5,6]. Ribavirin,
which leads to depletion of cellular GTP pool, has a broad spectrum
of antiviral activity [7]. Although several models have been raised
[8], the mechanism of ribavirin action remains controversial. Our
recent ﬁnding demonstrates that the anti-HCV effect of ribavirin
is partly attributed to the upregulation of the double-stranded
RNA-activated protein kinase activity [9]. Even though, other po-
tential mechanisms may also exist.
To further characterize the role of ribavirin in the combined
treatment with ribavirin and IFN, we investigated the ribavirin ef-
fects on p53 pathways in response to IFN signaling. This mimicked
the effects of ribavirin in the combination therapy with IFN and
ribavirin for HCV patients. We demonstrate that ribavirin activates
mTOR and p53, which in turn enhances the IFN signaling
pathways. These effects may explain the role of ribavirin in thelsevier B.V. All rights reserved.
Table 1
Induction of phosphorylated p53 and p53 downstream effectors, p21 and mdm2 in
various cell lines after 24 h of ribavirin treatment.
Cell lines p53 status Tissue source p53 serine-15 p21 mdm2
HCT116 WT Colon + + +
HepG2 WT Liver + + +
U2OS WT Bone + + +
MCF7 WT Breast + + +
A549 WT Lung + + +
Huh7 Mutant Liver   
Hep3B Null Liver   
H1299 Null Lung   
Note: All cells were treated with ribavirin(30 lg/mL) and harvested at 24 h. The
phosphorylation of p53 serine-15 was measured byWestern blot, normalized to the
expression of b-actin. Real-time RT-PCR was utilized to analyze the expression of
p21 and mdm2 in each cell line for three independent experiments. The change was
shown compared to that observed in the untreated cells, normalized to the
expression of TBP mRNA. Gene induction was calculated as gene expression levels
in ribavirin- treated cells compared to untreated controls (P value <0.05). +: More
than twofold induction; : less than twofold induction.
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provides a new attempt to elucidate the diverse role of ribavirin.
2. Materials and methods
2.1. Cell culture and reagents
HepG2, Huh7, A549, H1299 and 293T cells were maintained in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum and 100 units/mL of penicillin and strepto-
mycin. LY294002 (phospho-inositide 3-kinase (PI3K kinase inhibi-
tor)), rapamycin (mTOR kinase inhibitor), caffeine (mTOR and
ataxia telangiectasia mutated (ATM)/ATM- and Rad3-related pro-
tein (ATR) kinase inhibitor) [10], compound C (AMPK inhibitor),
MG132 (proteasome inhibitor), cisplatin and ribavirin were pur-
chased from Sigma–Aldrich. PD98059 (ERK kinase inhibitor) and
SB203580 (p38 kinase inhibitor) were from Promega and levovirin
from ICN Pharmaceuticals.
2.2. Quantitative RT-PCR (qRT-PCR) analysis
For qRT-PCR analysis, RNA was isolated from cells by TRIzol
(Invitrogene) according to manufacturer’s instructions. QRT-PCR
was performed using SYBR Premix Ex Taq II kit (TaKaRa) in a Smart
Cycler instrument (Chepheid). The primers used in this study have
been previously described [4,11].
2.3. Cytotoxicity, cell viability and cell death assays
Cytotoxicity was determined by trypan blue exclusion and
using the CytoTox-Glo cytotoxicity assay kit (Promega). Cell viabil-
ity was determined using MTT assay kit (Promega). Cell death was
detected by annexin-V/propidium iodide labeling (BD Biosciences),
and samples were analyzed using BD FACScalibur (BD Biosciences).Fig. 1. Ribavirin stimulates p53 activity. (A) A549 cells were treated with the indic
dehydrogenase (LDH) release assay. (B) Cell viability was determined by MTT assay. (C)
death (necrosis and apoptosis) by annexin-V/propidium iodide labeling. (D) Dose-depend
a positive control for apoptosis signaling. (E) p53 and p21 mRNA levels were analyzed by
untreated cells, after normalization based on the expression of TATA-binding protein (
independent experiments.2.4. Immunoprecipitation and Western blot analysis
The cells were harvested and lysed in an ice-cold lysis buffer
as previously described [12]. Blots were incubated with primary
antibody as follows: p53 (s15), raptor p70S6K (t389), p70S6K,
Akt (s473), Akt, PAK1 (t423), PAK1, and PARP were purchased
from Cell Signaling Technology. mTOR (N-19), p53 (DO-1), p53
(FL393), p21 (187) IRF9 (H-143), RIG-I (L-15), mdm2 (SMP14)
were from Santa Cruz Biotechnology. The remaining antibodies
are mTOR (mTAb1) (Upstate), rictor (Novus), b-actin (Sigma–Al-
drich), and p56 (LTK Biolaboratories). For all immunoprecipitation
experiments, the lysis buffer contained 0.3% CHAPS instead of 1%
Triton X-100 that preserved the integrity of mTOR complexes as
described [12].ated amounts of ribavirin for 3 days. Cytotoxic effect was examined by lactate
A549 cells were treated with ribavirin (30 lg/mL) for 2 days. FACS analysis of cell
ent activation of p53 by ribavirin in A549 cells. Cisplatin (4 lM) treatment serves as
quantitative RT-PCR. The fold change was shown compared to that observed in the
TBP) mRNA. Data shown in (A), (B), (C), and (E) represent the mean ± S.D. of three
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The wild-type and mutated p56-luciferase reporter constructs
were described previously [13]. Luciferase activity was normalized
to pRL-TK (Promega) and expressed as fold induction over that of
the control after 24 h of treatment.
2.6. shRNA lentiviruses
Plasmids encoding lentiviruses that express either scramble
sequence or shRNA against mTOR (Addgene plasmids 1855 and
1864, respectively) have been described [12]. The p53 shRNA plas-
mids were obtained from the RNAi Core Facility of Academia Sini-
ca. Lentiviruses were prepared in 293T cells following established
protocols [12].
2.7. Statistical analysis
The results are expressed as mean ± standard deviation (S.D.)
from at least three independent experiments. The statistical analy-
sis was performed using Student t-test and differences were con-
sidered statistically signiﬁcant at P < 0.05.Fig. 2. Activation of mTOR is required for stimulation of p53 activity by ribavirin. (A) The
A549 cells with ribavirin treatment were quantiﬁed using real-time RT-PCR. The fold cha
expression of TBP mRNA. Ribavirin (R) (30 lg/mL), wortmannin (Wort), compound C (CC
used. Each result represents the mean ± S.D. of three independent experiments. (B) The
with ribavirin. Actin levels serve as loading controls. (C) Ribavirin-induced activation
indicated proteins were analyzed using Western blot. The cells receiving rapamycin in
treatment is a positive control for p53 activity.3. Results and discussion
3.1. Ribavirin stimulates p53 activity
We ﬁrst measured the cytotoxic effects of ribavirin on A549
cells by trypan blue assay (data not shown), lactate dehydrogenase
(LDH) release (Fig. 1A), MTT assay (Fig. 1B) and annexin-V/propidi-
um iodide labeling (Fig. 1C). We found that ribavirin did not exert
cytotoxic effects. Instead, it showed signiﬁcant antiproliferative ef-
fects (Fig. 1B). These results suggest that the decline of cell viability
resulted from the inhibition of cell growth, since no cytotoxicity
was detected following ribavirin treatment. To explore the effects
of ribavirin on p53, we further treated A549 cells with incremental
doses of ribavirin or levovirin. Levovirin, a L-enantiomer of ribavi-
rin, possesses immunomodulatory activity similar to ribavirin, but
lacks direct antiviral activity [14]. Ribavirin elevated the activity of
p53 and increased the level of the p21 protein but did not affect
cleaved PARP (Fig. 1D). Interestingly, while ribavirin also regulated
the transcription of p21, it did not alter p53 mRNA levels (Fig. 1E).
Since p53 is a pleiotropic stress sensor and its response is tissue-
speciﬁc [15], it is possible that the p53 activity we observed above
may vary among different cell types. We, therefore, examined ainhibitory effects of different inhibitors on p53 activity. The levels of p21 mRNA of
nge was shown compared to that observed in the untreated cells, normalized to the
), Rapamycin (Ra), caffeine (Ca), LY294002 (LY), PD98059 (PD), SB203580 (SB) were
effects of different kinase inhibitors on the p21 protein levels of A549 cells treated
of p53 and mTOR in A549 cells at different time points following treatment. The
the presence of ribavirin serve as a negative control for mTOR activity. Cisplatin
Fig. 3. Suppression of mTOR activity inhibited p53 activity. (A) Ribavirin enhanced
the interaction of p53 and mTOR. Cell lysates were prepared from HepG2 cells
receiving the indicated treatment. Following immunoprecipitates (IP) with the anti-
mTOR antibody, cell lysates were analyzed for the indicated proteins using
immunoblot (IB) (right ﬁgure). All cells were pre-treated with MG132 (20 lM). U:
untreated; Ra: rapamycin; R: ribavirin. (B) mTOR knockdown inhibited p53 activity.
Twenty-four hours after addition of ribavirin, immunoblotting was used to analyze
the total amounts and phosphorylation states of the indicated proteins in HepG2
cells receiving either scramble or mTOR-speciﬁc shRNA. (C) The expression of p21
mRNA levels in the mTOR knockdown cells with ribavirin treatment. The fold
change was shown compared to that observed in the untreated cells, after
normalization based on the expression of TBP mRNA. Each result represents the
mean ± S.D. of three independent experiments.
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activity by ribavirin is tissue-speciﬁc. Following 24 h of ribavirin
treatment, the levels of phosphorylated p53, p21 and mdm2 were
signiﬁcantly increased in cells with wild-type p53, but not in p53-
mutant or -deﬁcient cell lines (Table 1). These data demonstrate
that activation of p53 by ribavirin is a common phenomenon
among different types of cells with wild-type p53. In addition, this
observation can also partly explain the inhibition of IMPDH by
ribavirin since IMPDH activity is downregulated by p53 [1]. Taken
together, our data demonstrate that ribavirin induces p53 activa-
tion is correlated with its effect on the suppression of tumor
growth.
3.2. Ribavirin-enhanced mTOR activation is required for p53
phosphorylation and accumulation
The serine-15 residue of p53 can be phosphorylated by several
members of the PI3K family, including DNA-PK, ATM, ATR, and
mTOR, as well as by stress kinases, particularly, AMP-activated ki-
nase (AMPK), ERK and p38 kinase [16–18]. The phosphorylation
of serine-15 leads to reduced interaction between p53 and mdm2,
promoting both the accumulation and activation of p53 [16]. To
understand how ribavirin increases p53 activity, we quantiﬁed
the effects of an array of kinase inhibitors that involve different
pathways on the expression of p21mRNA. LY294002 andwortman-
nin, both PI3K inhibitors inhibited the activity of p53 by ribavirin
treatment (Fig. 2A). Rapamycin, an inhibitor of mTOR, had similar
effects as LY294002 and wortmannin. Caffeine and PD98059 only
showed modest inhibition of p21 transcription. By contrast,
SB203580, a p38 kinase inhibitor, failed to prevent the activation
of p53 by ribavirin treatment. Surprisingly, the expression of p21
mRNA (Fig. 2A) and protein (Fig. 2B) were speciﬁcally enhanced
through a combined treatment with compound C, an AMPK inhibi-
tor, and ribavirin, suggesting that this combination treatment in-
duced a synergistic response of p53 activity. These results
indicate that increase of PI3K–Akt–mTOR activity correlates with
increase of p53 activity. To gain insight into mTOR pathways in-
volved in ribavirin-induced p53 activity, we monitored the effects
of ribavirin on the activation of p53 and mTOR at different time
points. Interestingly, we observed that ribavirin increased the activ-
ities of mTOR–p70S6K–PAK1, Akt and p53 (Fig. 2C), while rapamy-
cin signiﬁcantly inhibited that activation of p53 by ribavirin
(Fig. 2C). These results demonstrate that inhibition ofmTOR activity
attenuated p53 phosphorylation and accumulation, suggesting that
the enhancement of mTOR activity by ribavirin positively regulates
p53 activity. However, the ribavirin-induced activation of mTOR
activity by ribavirin was not only observed in p53 wild-type cells,
but also in p53-mutant and -deﬁcient cell lines (data not shown).
These data demonstrate that ribavirin-induced mTOR activity is a
common phenomenon in cell lines with or without functional p53.
3.3. Inhibition of mTOR activation attenuates p53 activity induced by
ribavirin
Rapamycin can disrupt the large multimeric complex contained
in mTOR complexes [19]. To test whether ribavirin-stimulated p53
activity is mediated by mTOR through enhanced interaction be-
tween mTOR and p53, we examined the physical interaction be-
tween mTOR and p53 by immunoprecipitation. As shown in
Fig. 3A, ribavirin treatment inducedbinding ofmTOR to p53, but this
effect was reduced in the presence of rapamycin.We have observed
that rictor, raptor and p53 dissociated frommTOR in ribavirin-trea-
ted cells receiving prolonged (24 h) rapamycin treatment (Fig. 3A).
These results suggest that ribavirin enhances the physical interac-
tion between mTOR and p53. To further investigate whether mTOR
is required for p53 activity, we silenced mTOR with shRNA. Neitherp21 nor the phosphorylated p53 was signiﬁcantly increased in the
ribavirin-treated cells receiving mTOR shRNA (Fig. 3B). In addition,
p21 protein expression was signiﬁcantly decreased in the mTOR
shRNA-silenced cells treated with rapamycin. The reduced p21
mRNA levels were also observed in mTOR knockdown cells receiv-
ing ribavirin treatment compared to that of the ribavirin-treated
cells receiving scramble shRNA (Fig. 3C). Interestingly, we noticed
that p21 protein levels inmTOR-silenced cellsweremore greatly re-
duced than those in the cells receivingmock shRNA. Consistentwith
our observation, a previous study reported that inhibition of mTOR
function by its inhibitor RAD001 reduces p21 protein expression,
but not p21 transcription, through selective inhibitionof protein ini-
tiation [20]. Together, these results suggest that mTOR activation is
required for ribavirin-induced activation of p53.
3.4. Ribavirin enhances IFN-a signaling through p53-dependent and
p53-independent pathways
Previous studies have demonstrated that ribavirin potentiates
respiratory syncytial virus-induced ISRE-dependent signaling to
Fig. 4. Ribavirin enhances IFN signaling through p53-dependent and p53-independent pathways. (A) Real-time RT-PCR analysis of the expression of IRF9, p56, and RIG-I in
p53 or mock (scramble shRNA) knockdown HepG2 cells receiving the treatment of IFN-a (100 U/mL) and/or ribavirin (30 lg/mL). The fold change was shown compared to
that observed in the untreated cells, normalized to the expression of TBP mRNA. U: untreated; R: ribavirin; I: IFN-a. (B) Western blot analysis of p53 expression normalized to
actin expression in HepG2 cells receiving scramble or p53-speciﬁc shRNA. (C) Western blot analysis of RIG-I, p56, and IRF9. Lysates of HepG2 were harvested after 4 h of the
indicated treatment. (D) Levels of luciferase expression in H1299 cells transfected with wild-type or mutated ISRE-containing p56-luciferase reporter constructs and receiving
the indicated treatment. (E) Levels of luciferase expression in Huh7 and H1299 cells transfected with the wild-type or mutated ISRE-containing p56-luciferase reporter
constructs. (F) Western blot analysis of RIG-I and p56. Lysates of H1299 were harvested after 4 h of the indicated treatment. Each result represents the mean ± S.D. of three
independent experiments.
Fig. 5. mTOR signaling plays an essential role in enhancing ISRE-dependent ISGs for the combination treatment with ribavirin and IFN. Real-time RT-PCR was utilized to
analyze the expression of p56, and RIG-I in mTOR or mock (scramble shRNA) knockdown HepG2 cells (A) or Huh7 cells (B). Both cell lines also received the indicated
treatment of IFN-a (100 U/mL) and/or ribavirin (30 lg/mL). The fold change was shown compared to that observed in the untreated cells, normalized to the expression of TBP
mRNA. U: untreated; R: ribavirin; I: IFN-a. Each result represents the mean ± S.D. of three independent experiments.
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contributes to the enhancement of IFN-a-dependent signaling
through the transcriptional induction of IRF9 [4]. To further inves-
tigate the contribution of ribavirin to the IFN response, we assessed
whether the induction of p53 activity by ribavirin also promoted
the transcription of IRF9 and ISRE-dependent ISGs. We examined
the mRNA levels of IRF9 and other ISRE-dependent ISGs, including
RIG-I and p56 in scramble shRNA-treated and p53 knockdown cells
with the treatment of IFN and/or ribavirin. As shown in Fig. 4A and
B, p53 expression was critical for the increase of IRF9, p56 and RIG-
I mRNA in the cells receiving the treatment of IFN and/or ribavirin.
The combined treatment with ribavirin and IFN exhibited the
strongest stimulatory effect on the transcription of these genes.
This effect was also observed at the protein levels (Fig. 4C). To fur-
ther determine whether this effect was mediated by ISRE-depen-
dent transcription, we performed the p56 promoter assay in p53-
deﬁcient H1299 cells in the presence of p53 and/or IFN. Two ISRE
consensus sites are present in the promoter of p56 [13]. Mutation
of both ISRE binding sites completely abrogated the induction of
p56 by p53 and/or IFN (Fig. 4D). All of these results suggest that
ribavirin stimulates p53 activity that in turn enhances ISRE-depen-
dent signaling in the cells receiving combination treatment with
ribavirin and IFN. Speciﬁcally, the functional p53 plays a critical
role in enhancing IFN signaling [4]. To evaluate whether activation
of p53 is solely responsible for ribavirin-enhanced IFN signaling,
we again performed a p56 promoter assay in Huh7 cells, which
harbor a p53 Y220C mutant, and H1299 cells receiving the treat-
ment with IFN and/or ribavirin. It is known that p53 with the
mutation Y220C abolishes its transcriptional activity [4]. Surpris-
ingly, the synergistic effect of IFN and ribavirin were still observed
in Huh7 and H1299 cells (Fig. 4E). Consistently, the protein levels
of p56 and RIG-I were also upregulated (Fig. 4F). This indicates that
ribavirin stimulates IFN response pathways independent of p53.
Altogether, these results support that ribavirin enhances ISRE-
dependent ISGs for the combined treatment with IFN and ribavirin
via both p53-dependent and p53-independent pathways.
3.5. Ribavirin-stimulated mTOR activity enhances ISRE-dependent
ISGs
Since we have shown that mTOR activity is required for p53
activation induced by ribavirin, we further determined whether
mTOR enhances ISRE-dependent ISGs for the combined treatment
with IFN and ribavirin. In particular, the effect of mTOR was ex-
plored in the context of p53-dependency. Compared to IFN treat-
ment alone, the combined treatment with IFN and ribavirin in
either p53 wild-type or mutant cell lines with knockdown of mTOR
failed to show the synergistic effects on the transcription of p56
and RIG-I (Fig. 5A and B). These results indicate that the enhance-
ment of IFN signaling by ribavirin is absolutely mTOR-dependent.
The coordinated function of mTOR and IFN pathways has been
shown before. It is known that Akt activity is required for mRNA
translation of ISGs via mTOR pathway [22]. Nevertheless, we found
that mTOR signaling is required to enhance ISRE-dependent tran-
scription during for the combined treatment with ribavirin and
IFN. Therefore, the mechanisms involving the coordination and
communication between mTOR and ISRE-dependent transcription
deserve further investigation.
In conclusion, ribavirin upregulates the ISRE-dependent ISGs to
augment IFN signaling by stimulation of mTOR and p53. While
both p53-dependent and p53-independent pathways play a role
in ribavirin-induced IFN response, mTOR is absolutely required
for the effects of ribavirin. This has an important implication in
the combination therapy with ribavirin and IFN for patients with
chronic hepatitis C. Although no direct antiviral experiments wereshown in this model, our study strongly suggest a novel role of
ribavirin in the IFN-dependent antiviral and antitumor signaling
through activation of mTOR and p53. It also raises interesting is-
sues regarding ribavirin treatment that remains to be elucidated
in further studies.Acknowledgements
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